{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:29:26Z","timestamp":1792106966460,"version":"4.4.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The remarkable efficacy of Epstein-Barr virus (EBV)-specific T cells for the treatment of posttransplant lymphomas has not been reproduced for EBV-positive (EBV+) malignancies outside the transplant setting. This is because of, in part, the heterogeneous expression and poor immunogenicity of the viral antigens expressed, namely latent membrane proteins 1 and 2, EBV nuclear antigen 1, and BamHI A rightward reading frame 1 (type-2 [T2] latency). However, EBV lytic cycle proteins are also expressed in certain EBV+ malignancies and, because several EBV lytic cycle proteins are abundantly expressed, have oncogenic activity, and likely contribute to malignancy, we sought and identified viral lytic-cycle transcripts in EBV+ Hodgkin lymphoma biopsies. This provided the rationale for broadening the target antigen\u2013specific repertoire of EBV-specific T cells (EBVSTs) for therapy. We stimulated, peripheral blood mononuclear cells from healthy donors and patients with EBV+ lymphoma with both lytic and latent cycle proteins to produce broad repertoire (BR) EBVSTs. Compared with T2 antigen-specific EBVSTs, BR-EBVSTs more rapidly cleared autologous EBV+ tumors in NOD.Cg-Prkdcscid Il2rgtm1Wjl\/SzJ (NSG)\u00a0mice and produced higher levels of proinflammatory cytokines that should reactivate the immunosuppressive tumor microenvironment leading to epitope spreading. Our results confirm that lytic cycle antigens are clinically relevant targets for EBV+ lymphoma and underpin the rationale for integrating BR-EBVSTs as a therapeutic approach for relapsed\/refractory EBV+ lymphoma (www.clinicaltrials.gov identifiers: #NCT01555892 and #NCT04664179), as well as for other EBV-associated malignancies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012183","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T18:07:54Z","timestamp":1713550074000},"page":"3360-3371","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-1894","authenticated-orcid":false,"given":"Sandhya","family":"Sharma","sequence":"first","affiliation":[{"name":"1Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX"},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital, and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-3592","authenticated-orcid":false,"given":"Naren U.","family":"Mehta","sequence":"additional","affiliation":[{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital, and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-324X","authenticated-orcid":false,"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital, and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Rollins","sequence":"additional","affiliation":[{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital, and Houston Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5656","authenticated-orcid":false,"given":"Dirk P.","family":"Dittmer","sequence":"additional","affiliation":[{"name":"3Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-2864","authenticated-orcid":false,"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[{"name":"1Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX"},{"name":"2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children\u2019s Hospital, and Houston Methodist Hospital, Houston, TX"},{"name":"4Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX"},{"name":"5Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX"},{"name":"6Department of Pathology-Immunology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"1","key":"2024070912553620000_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"issue":"1","key":"2024070912553620000_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"2024070912553620000_bib3","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024070912553620000_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"issue":"7750","key":"2024070912553620000_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"12","key":"2024070912553620000_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"1732","key":"2024070912553620000_bib7","doi-asserted-by":"crossref","first-page":"20160264","DOI":"10.1098\/rstb.2016.0264","article-title":"Human oncogenic viruses: nature and discovery","volume":"372","author":"Chang","year":"2017","journal-title":"Phil Trans Biol Sci"},{"issue":"12","key":"2024070912553620000_bib8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nrc2961","article-title":"Why do viruses cause cancer? Highlights of the first century of human tumour virology","volume":"10","author":"Moore","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2024070912553620000_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2024070912553620000_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2024070912553620000_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr virus-associated lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin Oncol"},{"issue":"8","key":"2024070912553620000_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024070912553620000_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.01709","article-title":"Adoptive T-cell therapy for Epstein-Barr virus\u2013related lymphomas","volume":"39","author":"Heslop","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8941","key":"2024070912553620000_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"2024070912553620000_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3816\/CLM.2006.n.011","article-title":"Administration of latent membrane protein 2\u2013specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus\u2013positive lymphoma","volume":"6","author":"Bollard","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"2024070912553620000_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2024070912553620000_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2024070912553620000_bib18","doi-asserted-by":"crossref","first-page":"e006267","DOI":"10.1136\/jitc-2022-006267","article-title":"Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy","volume":"11","author":"Sharma","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2024070912553620000_bib19","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/340637","article-title":"Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals","volume":"185","author":"Kern","year":"2002","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"2024070912553620000_bib20","first-page":"193","article-title":"Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity","volume":"37","author":"Ngo","year":"2014","journal-title":"J\u00a0Immunother"},{"issue":"16","key":"2024070912553620000_bib21","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1128\/JVI.76.16.8179-8188.2002","article-title":"The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules","volume":"76","author":"Keating","year":"2002","journal-title":"J\u00a0Virol"},{"issue":"9","key":"2024070912553620000_bib22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1084\/jem.185.9.1605","article-title":"Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response","volume":"185","author":"Steven","year":"1997","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2024070912553620000_bib23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1128\/JVI.74.3.1224-1233.2000","article-title":"Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases","volume":"74","author":"Adamson","year":"2000","journal-title":"J Virol"},{"issue":"12","key":"2024070912553620000_bib24","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J"},{"issue":"1","key":"2024070912553620000_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-9378-7-21","article-title":"Epstein-Barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile","volume":"7","author":"Tang","year":"2012","journal-title":"Infect Agent Cancer"},{"issue":"pt 6","key":"2024070912553620000_bib26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1099\/0022-1317-76-6-1401","article-title":"Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies","volume":"76","author":"Martel-Renoir","year":"1995","journal-title":"J\u00a0Gen Virol"},{"issue":"1","key":"2024070912553620000_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11684-016-0436-0","article-title":"Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing","volume":"10","author":"Hu","year":"2016","journal-title":"Front Med"},{"key":"2024070912553620000_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2014.10.030","article-title":"Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA","volume":"474","author":"Tierney","year":"2015","journal-title":"Virology"},{"issue":"2","key":"2024070912553620000_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/v15020423","article-title":"Comprehensive profiling of EBV gene expression and promoter methylation reveals latency II viral infection and sporadic abortive lytic activation in peripheral T-cell lymphomas","volume":"15","author":"Ho","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"2024070912553620000_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers10040098","article-title":"The immunomodulatory capacity of an Epstein-Barr virus abortive lytic cycle: potential contribution to viral tumorigenesis","volume":"10","author":"Morales-S\u00e1nchez","year":"2018","journal-title":"Cancers"},{"key":"2024070912553620000_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein-Barr virus","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2024070912553620000_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2024070912553620000_bib33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat Microbiol"},{"issue":"3","key":"2024070912553620000_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.20041542","article-title":"CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells","volume":"201","author":"Pudney","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"2024070912553620000_bib35","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1371\/journal.pone.0000583","article-title":"Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy","volume":"2","author":"Adhikary","year":"2007","journal-title":"PLoS One"},{"issue":"2","key":"2024070912553620000_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<151::AID-PATH824>3.0.CO;2-3","article-title":"Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells","volume":"182","author":"Niedobitek","year":"1997","journal-title":"J\u00a0Pathol"},{"issue":"8","key":"2024070912553620000_bib37","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1002\/jmv.26936","article-title":"Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder","volume":"93","author":"Zaffiri","year":"2021","journal-title":"J\u00a0Med Virol"},{"issue":"8","key":"2024070912553620000_bib38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-18-0940","article-title":"Systemic interferon-\u03b3 increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2024070912553620000_bib39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0022-1759(88)90079-8","article-title":"Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells","volume":"110","author":"Czerkinsky","year":"1988","journal-title":"J\u00a0Immunol Methods"},{"issue":"14","key":"2024070912553620000_bib40","doi-asserted-by":"crossref","first-page":"R498","DOI":"10.1016\/S0960-9822(98)70317-3","article-title":"Anti-viral immunity: spotting virus-specific T cells","volume":"8","author":"Tough","year":"1998","journal-title":"Curr Biol"},{"issue":"19","key":"2024070912553620000_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01062-18","article-title":"Mutant cellular AP-1 proteins promote expression of a subset of Epstein-Barr virus late genes in the absence of lytic viral DNA replication","volume":"92","author":"Lyons","year":"2018","journal-title":"J Virol"},{"issue":"1","key":"2024070912553620000_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hon.2465","article-title":"Epstein-Barr virus lytic cycle involvement in diffuse large B cell lymphoma","volume":"36","author":"Cohen","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"2024070912553620000_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.10372","article-title":"Promiscuous expression of Epstein-Barr virus genes in Burkitt\u2019s lymphoma from the central African country Malawi","volume":"99","author":"Xue","year":"2002","journal-title":"Int J Cancer"},{"issue":"8","key":"2024070912553620000_bib45","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.27439","article-title":"Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma","volume":"131","author":"Hui","year":"2012","journal-title":"Int J Cancer"},{"issue":"5","key":"2024070912553620000_bib42","doi-asserted-by":"crossref","first-page":"e26302","DOI":"10.1002\/pbc.26302","article-title":"Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: longitudinal results from the Kamuzu Central Hospital Lymphoma study","volume":"64","author":"Westmoreland","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2024070912553620000_bib46","doi-asserted-by":"crossref","first-page":"575255","DOI":"10.3389\/fmicb.2020.575255","article-title":"Direct evidence of abortive lytic infection-mediated establishment of Epstein-Barr virus latency during B-cell infection","volume":"11","author":"Inagaki","year":"2020","journal-title":"Front Microbiol"},{"issue":"1","key":"2024070912553620000_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"2024070912553620000_bib48","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cyto.2008.07.014","article-title":"Cytokines as a key component of cancer-related inflammation","volume":"43","author":"Germano","year":"2008","journal-title":"Cytokine"},{"issue":"12","key":"2024070912553620000_bib49","doi-asserted-by":"crossref","first-page":"e15625","DOI":"10.1371\/journal.pone.0015625","article-title":"Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines","volume":"5","author":"Tran","year":"2010","journal-title":"PLoS One"},{"issue":"3-4","key":"2024070912553620000_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int Rev Immunol"},{"issue":"22","key":"2024070912553620000_bib51","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.3390\/cancers13225833","article-title":"HLA expression in relation to HLA type in classic Hodgkin lymphoma patients","volume":"13","author":"Tan","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2024070912553620000_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","article-title":"Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas","volume":"54","author":"Dersh","year":"2021","journal-title":"Immunity"},{"key":"2024070912553620000_bib53","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3389\/fimmu.2019.02679","article-title":"The pleiotropic effects of the GM-CSF rheostat on myeloid cell differentiation and function: more than a numbers game","volume":"10","author":"Zhan","year":"2019","journal-title":"Front Immunol"},{"issue":"15","key":"2024070912553620000_bib54","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","article-title":"Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy","volume":"119","author":"van de Laar","year":"2012","journal-title":"Blood"},{"issue":"pt 1","key":"2024070912553620000_bib55","first-page":"151","article-title":"Thorley-Lawson DA EBV persistence-introducing the virus","volume":"390","year":"2015","journal-title":"Epstein Barr Virus"},{"issue":"4","key":"2024070912553620000_bib56","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4049\/jimmunol.167.4.2019","article-title":"EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function","volume":"167","author":"Hislop","year":"2001","journal-title":"J Immunol"},{"key":"2024070912553620000_bib57","doi-asserted-by":"crossref","first-page":"483952","DOI":"10.3389\/fimmu.2019.02193","article-title":"The T-cell response to Epstein-Barr virus\u2013new tricks from an old dog","volume":"10","author":"Long","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"2024070912553620000_bib58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2024070912553620000_bib59","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"2024070912553620000_bib60","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2024070912553620000_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40778-020-00170-6","article-title":"Virus-specific T cells for the treatment of malignancies\u2014then, now, and the future","volume":"6","author":"Sharma","year":"2020","journal-title":"Curr Stem Cell Rep"},{"issue":"6","key":"2024070912553620000_bib62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(02)00266-7","article-title":"High tumor necrosis factor-alpha levels in the patients with Epstein-Barr virus-associated peripheral T-cell proliferative disease\/lymphoma","volume":"27","author":"Mori","year":"2003","journal-title":"Leuk Res"},{"issue":"1","key":"2024070912553620000_bib63","doi-asserted-by":"crossref","first-page":"10813","DOI":"10.1038\/s41598-017-11052-z","article-title":"Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact","volume":"7","author":"Cohen","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2024070912553620000_bib64","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1186\/s12885-022-09942-1","article-title":"Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA","volume":"22","author":"Yuan","year":"2022","journal-title":"BMC Cancer"},{"issue":"9","key":"2024070912553620000_bib65","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/491741","article-title":"Differential targeting and shifts in the immunodominance of Epstein-Barr virus\u2013specific CD8 and CD4\u00a0T cell responses during acute and persistent infection","volume":"192","author":"Woodberry","year":"2005","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"2024070912553620000_bib66","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2024070912553620000_bib67","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/cancers12082142","article-title":"Lytic induction therapy against Epstein\u2013Barr virus-associated malignancies: past, present, and future","volume":"12","author":"Yiu","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"2024070912553620000_bib68","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A\u00a0phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3360\/2233943\/blooda_adv-2023-012183-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/13\/3360\/2233943\/blooda_adv-2023-012183-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:56:35Z","timestamp":1720529795000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/13\/3360\/515788\/Cotargeting-EBV-lytic-as-well-as-latent-cycle"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":68,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012183","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}